Skyscape Web Viewer : Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs : Main Index

View All
ABC
absolute neutrophil count (ANC) Answer 3.2 Question 3.2 Answer 11.4 Answer 3.5
ACTH
acute kidney injury (AKI) Question 3.4 Antifolate Toxicities and Supportive Agents
acute lymphoblastic leukemia (ALL) Asparaginases, as Amidohydrolases, Possess Both Asparaginase and Glutaminase Activity Polymorphism in Thiopurine Methyltransferase (TPMT) Question 3.6 Question 5.2 Answer 5.2 Immunotherapeutics Including Vaccines, Bispecifics, CAR-T, and Checkpoint Inhibitors Purine Analogs Question 3.7
acute myeloid leukemia (AML) Question 15.3 Question 15.1 Targeted Therapies (Small Molecules)
acute promyelocytic leukemia (APL) Differentiating Agents and Microenvironment Question 8.1
acute respiratory distress syndrome (ARDS)
ADC
ADCP
adenosine triphosphate (ATP) Targeted Therapies (Small Molecules) Tyrosine Kinase Inhibitors (TKI)
adoptive T-cell therapies (ACT)
adrenocorticotropic hormone (ACTH) Male Hormonal Therapies Chemical Structures of Abiraterone and its Prodrug, Abiraterone Acetate Sources of and rogens in the Human Prostate
ADT
AE
AKI
alanine transaminase (ALT)
ALDH
Alkylating agents cyclophosphamide and ifosfamide methylguanine methyltransferase, clinical importance platinum compounds triazines (three attached nitrogen atoms) ethylenimines nitrosoureas treatment goal
allo-hematopoietic stem cell transplantation (HSCT) Answer 15.3 Answer 15.5 Question 15.1 Question 15.3 Transplant-Related Agents Answer 15.4 Mechanism of Action of High-Dose Cyclophosphamide Graft-Versus-Host Disease (GVHD) Prophylaxis Question 15.2 Question 15.4
all-trans retinoic acid (ATRA) Differentiating Agents and Microenvironment Answer 8.2 Question 8.1
ALT
aminotransferase (AST)
anaplastic lymphoma kinase (ALK) Anaplastic Lymphoma Kinase (ALK) Fusion Targeted Therapies (Small Molecules)
ANC
and rogen deprivation therapy (ADT) Overview of Prostate Cancer (PC) Progression and Treatment Male Hormonal Therapies Question 10.2
and rogen receptor (AR) Male Hormonal Therapies Physiological and Anatomical Targets of FDA-Approved "Hormonal" Drugs for Prostate Cancer Molecular Mechanism of and rogen Receptor (AR) Activation by Dihydrotestosterone (DHT)
antibody-dependent cell-mediated cytotoxicity (ADCC) Components of 90y-Ibritumomab Tiuxetan Novel Therapeutic Strategies in Oncology Naked Monoclonal Antibody Mechanism of Action
antibody-dependent cellular phagocytosis (ADCP)
antibody-drug conjugates (ADC) Multiple Myeloma as a Paradigm for Multi-Targeted Intervention Monoclonal Antibodies Including Immunoconjugates and Cytokine-Directed Agents